Testicular cancer developed in a chronic myeloid leukemia patient with a continued complete cytogenetic and molecular response to imatinib. A case report and review of the literature. - Suppr | 超能文献

Testicular cancer developed in a chronic myeloid leukemia patient with a continued complete cytogenetic and molecular response to imatinib. A case report and review of the literature.

作者信息

Kata Dariusz, Mrówka-Kata Katarzyna, Seweryn Marek, Pajak Jacek, Najda Jacek, Kyrcz-Krzemień Sławomira

出版信息

Leuk Res. 2010 Sep;34(9):e229-31. doi: 10.1016/j.leukres.2010.03.019. Epub 2010 Mar 31.

DOI:10.1016/j.leukres.2010.03.019

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Testicular cancer developed in a chronic myeloid leukemia patient with a continued complete cytogenetic and molecular response to imatinib. A case report and review of the literature.

Leuk Res. 2010 Sep;34(9):e229-31. doi: 10.1016/j.leukres.2010.03.019. Epub 2010 Mar 31.

2

Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.预测伊马替尼治疗的慢性髓性白血病患者分子和细胞遗传学反应的因素。

Haematologica. 2005 Jan;90(1):131-3.

3

Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.一名慢性髓性白血病患者在接受伊马替尼治疗后维持主要细胞遗传学反应，却出现了孤立的中枢神经系统原始细胞危象。

J Clin Oncol. 2006 Aug 20;24(24):4028-9. doi: 10.1200/JCO.2006.05.5608.

4

Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.伊马替尼治疗伴有非典型核型和BCR-ABL b2a3转录本的慢性髓性白血病患者后的完全细胞遗传学和分子反应

Cancer Genet Cytogenet. 2007 Apr 15;174(2):111-5. doi: 10.1016/j.cancergencyto.2006.11.021.

5

[Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].[采用实时定量逆转录聚合酶链反应监测甲磺酸伊马替尼治疗的慢性髓性白血病患者的bcr/abl mRNA水平]

Zhonghua Xue Ye Xue Za Zhi. 2005 Jan;26(1):1-5.

6

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.甲磺酸伊马替尼治疗慢性期慢性粒细胞白血病患者的分子反应

Clin Cancer Res. 2005 May 1;11(9):3425-32. doi: 10.1158/1078-0432.CCR-04-2139.

7

Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.对甲磺酸伊马替尼完全细胞遗传学反应的慢性髓性白血病患者的克隆性细胞遗传学异常

Haematologica. 2005 Apr;90(4):556-8.

8

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.在接受伊马替尼治疗的慢性髓性白血病患者中，在获得完全细胞遗传学缓解（CCgR）时达到主要分子学缓解预示着CCgR的持续时间更长。

Clin Cancer Res. 2006 May 15;12(10):3037-42. doi: 10.1158/1078-0432.CCR-05-2574.

9

Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.利妥昔单抗联合伊马替尼用于同时存在的治疗相关慢性粒细胞白血病和复发性非霍奇金淋巴瘤的联合治疗

Leuk Res. 2008 Feb;32(2):353-5. doi: 10.1016/j.leukres.2007.07.023. Epub 2007 Sep 7.

10

Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.获得性免疫缺陷综合征患者的慢性髓性白血病：甲磺酸伊马替尼治疗后完全细胞遗传学缓解：一例报告并文献复习

Leuk Res. 2004 Jun;28(6):657-60. doi: 10.1016/j.leukres.2003.10.020.

引用本文的文献

1

Testicular choriocarcinoma: a rare variant that requires a unique treatment approach.睾丸绒毛膜癌：一种需要独特治疗方法的罕见变体。

Curr Oncol Rep. 2015 Feb;17(2):2. doi: 10.1007/s11912-014-0430-0.

2

Occurrence of secondary malignancies in chronic myeloid leukemia during therapy with imatinib mesylate-single institution experience.甲磺酸伊马替尼治疗慢性髓性白血病期间继发恶性肿瘤的发生情况——单机构经验

Mediterr J Hematol Infect Dis. 2015 Jan 1;7(1):e2015003. doi: 10.4084/MJHID.2015.003. eCollection 2015.